AVTR logo

Avantor, Inc. Stock Price

NYSE:AVTR Community·US$9.2b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 18 Fair Values set on narratives written by author

AVTR Share Price Performance

US$13.75
-11.02 (-44.49%)
22.1% undervalued intrinsic discount
US$17.65
Fair Value
US$13.75
-11.02 (-44.49%)
27.6% undervalued intrinsic discount
US$19.00
Fair Value
Price US$13.75
AnalystHighTarget US$19.00
AnalystConsensusTarget US$14.15
AnalystLowTarget US$12.00

AVTR Community Narratives

AnalystHighTarget·
Fair Value US$17.65 22.1% undervalued intrinsic discount

Secular Trends And Cell Therapies Will Expand Markets Despite Risks

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$14.12 2.6% undervalued intrinsic discount

Pharma Contracts And R&D Will Drive Growth Amid Price Pressures

0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AnalystLowTarget·
Fair Value US$12 14.6% overvalued intrinsic discount

Digital Transformation And Rising Costs Will Undermine Lab Chemicals Sector

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent AVTR News & Updates

We Think Avantor (NYSE:AVTR) Is Taking Some Risk With Its Debt

Sep 12
We Think Avantor (NYSE:AVTR) Is Taking Some Risk With Its Debt

Concerns Surrounding Avantor's (NYSE:AVTR) Performance

Aug 12
Concerns Surrounding Avantor's (NYSE:AVTR) Performance

Avantor, Inc. Key Details

US$6.7b

Revenue

US$4.4b

Cost of Revenue

US$2.2b

Gross Profit

US$1.5b

Other Expenses

US$687.4m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 29, 2025
Earnings per share (EPS)
1.01
Gross Margin
33.25%
Net Profit Margin
10.31%
Debt/Equity Ratio
67.0%

Avantor, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Undervalued with proven track record.

3 Risks
3 Rewards

About AVTR

Founded
1904
Employees
13500
CEO
Emmanuel Ligner
WebsiteView website
www.avantorsciences.com

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 0.4%
  • 3 Months: 7.8%
  • 1 Year: 17.8%
  • Year to Date: 14.7%
Over the last 7 days, the market has remained flat, although notably the Healthcare sector gained 3.7% in that time. As for the longer term, the market has risen 18% in the past 12 months. Earnings are forecast to grow by 15% annually. Market details ›